What you'll find here at MDLinx Rheumatology: The top rheumatology clinical articles of the day, plus MDLinx exclusive content
Your Unread Messages in Rheumatology
See All >> Messages include industry-sponsored communications and special communications from MDLinx
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Hypovitaminosis D common in SLE
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
Smartest Doc Challenge
MDLinx
Clinical Pearls for Rheumatologists
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
1 Steroid injection for inferior heel pain: a randomised controlled trial Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
2 Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
3 Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study) Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
4 Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
5 A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
6 Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
7 Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
8 Efficacy of rituximab in systemic manifestations of primary Sjogrens syndrome: results in 78 patients of the AutoImmune and Rituximab registry Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
9 Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry Annals of Rheumatic Diseases, May 22, 2013 Clinical Article
10 Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) Annals of Rheumatic Diseases, May 21, 2013 Clinical Article
11 A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Annals of Rheumatic Diseases, May 21, 2013 Clinical Article
12 Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study Annals of Rheumatic Diseases, May 21, 2013 Clinical Article
13 Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives Expert Opinion on Pharmacotherapy, May 21, 2013 Clinical Article
14 Behcet Disease-associated Uveitis Successfully Treated with Golimumab Ocular Immunology and Inflammation, May 21, 2013 Clinical Article
15 Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis Clinical and Experimental Rheumatology Online, May 20, 2013 Evidence Based Medicine Review Article Clinical Article
16 Validation of methotrexate-first strategy in early poor prognosis rheumatoid arthritis: Results from a randomized, double-blind, 2-year trial Arthritis & Rheumatism, May 20, 2013 Clinical Article
17 Diabetes and gout: efficacy and safety of febuxostat and allopurinol Diabetes, Obesity and Metabolism, May 20, 2013 Clinical Article
18 Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis Rheumatology International, May 20, 2013 Evidence Based Medicine Review Article Clinical Article
19 Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcets Disease Renal Failure, May 20, 2013
20 Bisphosphonate use and subsequent hip fracture in South Korea Osteoporosis International, May 20, 2013 Clinical Article
In a study involving 74 patients with juvenile idiopathic arthritis (JIA), 26 patients had detectable anti-citrullinated protein antibodies (ACPA). The ACPA titers correlated with disease progression at baseline and after a median follow-up of 11.5 months. In addition to predicting disease severity and progression, the authors concluded that ACPA were superior to IgM-RF in diagnosing JIA.
Read the article summaryIn a study involving 208 patients with SLE followed for 12 years, 42 deaths occurred, 48% of which were considered to be cardiovascular mortalities. Age, increased cystatin C levels, and arterial disease were predictive of all-cause mortality. Cigarette smoking and increased sVCAM-1, hsCRP, abeta2GP1, and aPL antibody levels were predictive of cardiovascular mortality.
Read the article summaryIn a study conducted at the University of Geneva involving 118 patients with rheumatoid arthritis, but without cardiovascular disease at baseline, the 10-year Framingham cardiovascular risk score (FRS) was improved with the inclusion of the anti-apoA-1 antibody titer. The median follow-up was 9 years and the incidence of cardiovascular disease was 16%. Other biomarkers, including the NT-proBNP, oxLDL, CRP, and RF levels and the anti-citrullinated peptide antibody titer, did not improve the FRS.
Read the article summaryIndexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatology more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close